Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Active Pharma Ingredients

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737331

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1737331

Peptide API

PUBLISHED:
PAGES: 370 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Peptide API Market to Reach US$33.5 Billion by 2030

The global market for Peptide API estimated at US$10.9 Billion in the year 2024, is expected to reach US$33.5 Billion by 2030, growing at a CAGR of 20.5% over the analysis period 2024-2030. GLP-1 Receptor Agonist, one of the segments analyzed in the report, is expected to record a 19.9% CAGR and reach US$17.6 Billion by the end of the analysis period. Growth in the Insulin segment is estimated at 21.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 27.4% CAGR

The Peptide API market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 27.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 18.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.2% CAGR.

Global Peptide API Market - Key Trends & Drivers Summarized

Why Are Peptide APIs Gaining Strategic Importance in Drug Discovery and Therapeutic Innovation?

Peptide Active Pharmaceutical Ingredients (APIs) have emerged as one of the most promising segments in modern drug development, offering high specificity, potency, and safety across a wide range of therapeutic indications. Derived from short chains of amino acids, peptide APIs are biologically active compounds that mimic endogenous molecules and interact with specific targets such as receptors, enzymes, and ion channels. Their unique mode of action, favorable pharmacokinetics, and low toxicity make them highly valuable in treating cancer, metabolic disorders, cardiovascular diseases, and rare genetic conditions.

The increasing success of peptide-based drugs such as liraglutide, semaglutide, buserelin, and leuprolide has demonstrated the clinical viability of peptides, propelling pharmaceutical firms to invest in specialized R&D and scalable manufacturing platforms. With the shift toward precision medicine and biologics, peptides are bridging the gap between small molecules and large proteins, offering opportunities for novel therapeutic modalities, including cell-penetrating peptides, peptide-drug conjugates, and multifunctional peptides. The expanding pipeline of peptide therapeutics across clinical phases underscores the rising demand for high-purity, cost-efficient peptide APIs.

How Are Advances in Synthesis Techniques and Process Optimization Enhancing API Manufacturing Capabilities?

The evolution of solid-phase peptide synthesis (SPPS), liquid-phase synthesis, and hybrid techniques has significantly improved the scalability, purity, and throughput of peptide API production. Automated peptide synthesizers, improved resins, and optimized coupling reagents now enable efficient synthesis of long, complex, and cyclic peptides with reduced reaction time and waste generation. Additionally, innovations in purification technologies such as preparative HPLC, ion-exchange chromatography, and ultrafiltration have enhanced yield and impurity control.

Manufacturers are investing in continuous manufacturing platforms and high-throughput parallel synthesis systems to reduce batch variability and enable rapid scale-up for clinical and commercial supply. Moreover, regulatory expectations for ICH Q11 compliance, process validation, and impurity profiling are driving the adoption of advanced analytics and quality-by-design (QbD) frameworks. Peptide modification strategies, including lipidation, PEGylation, and cyclization, are being integrated at the API stage to enhance bioavailability and stability. These advancements are improving cost-efficiency, regulatory compliance, and therapeutic performance across the peptide value chain.

Which Therapeutic Areas and Regional Markets Are Fueling Global Demand for Peptide APIs?

Metabolic diseases-especially Type 2 diabetes and obesity-remain the primary therapeutic drivers for peptide APIs, given the commercial success of GLP-1 analogs. Oncology, endocrinology, urology, and reproductive health are also major therapeutic domains utilizing peptides for hormone regulation, tumor suppression, and targeted therapy delivery. Peptides are increasingly being used in orphan drug development, vaccine formulations, and infectious disease management, including antimicrobial and antiviral applications.

North America and Europe dominate peptide API consumption due to strong biopharmaceutical pipelines, advanced manufacturing capabilities, and regulatory maturity. The U.S. leads in innovation, clinical trials, and commercialization, while Germany, Switzerland, and Belgium are major manufacturing hubs. Asia-Pacific-particularly India, China, South Korea, and Japan-is rapidly expanding its footprint as a cost-efficient supplier of peptide APIs and contract manufacturing services (CDMOs). Regional players are scaling up to meet the needs of both branded innovators and biosimilar developers, creating a globally integrated and competitive market landscape.

What Is Driving Long-Term Growth and Strategic Transformation in the Peptide API Market?

The growth in the peptide API market is driven by rising clinical success rates of peptide drugs, strong R&D investment in biologics, and increasing preference for targeted therapies. As pharmaceutical pipelines diversify and regulatory agencies encourage orphan drug development, peptide APIs are gaining ground as scalable, versatile therapeutic platforms. The global expansion of contract development and manufacturing services (CDMO) is also driving API outsourcing, with specialized peptide facilities in high demand for GMP-compliant, cost-competitive production.

Strategically, companies are adopting vertical integration, partnering with biotech firms for co-development, and investing in dual manufacturing sites for supply resilience. The convergence of peptide synthesis with computational biology, AI-based drug design, and nanotechnology is opening new frontiers in personalized medicine and advanced delivery systems. As regulatory frameworks continue to evolve to accommodate peptide therapeutics, API manufacturers that offer flexible, end-to-end solutions with robust quality systems are well-positioned to lead this high-growth segment.

SCOPE OF STUDY:

The report analyzes the Peptide API market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (GLP-1 Receptor Agonist, Insulin, Other Peptide Classes); Administration Route (Oral Route, Parenteral Route); Application (Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application, Non-alcoholic Fatty Liver Disease Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Aji Bio-Pharma Services
  • AmbioPharm, Inc.
  • Anthem Biosciences
  • Bachem Holding AG
  • Biocon Limited
  • Biopeptek Pharmaceuticals
  • CordenPharma International
  • CPC Scientific Inc.
  • Creative Peptides
  • GenScript Biotech Corp.
  • Hybio Pharmaceutical Co.
  • Innovent Biologics
  • Lonza Group AG
  • Merck KGaA
  • Peptide Institute, Inc.
  • PeptiDream Inc.
  • PeptiStar Inc.
  • PolyPeptide Group
  • ScinoPharm Taiwan, Ltd.
  • Teva Active Pharmaceutical Ingredients

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34177

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Peptide API - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Peptide-Based Therapeutics Propels Demand for High-Purity Peptide APIs
    • Expansion of Chronic Disease and Cancer Treatment Pipelines Drives Clinical Uptake of Peptide Drugs
    • Advancements in Solid-Phase Synthesis and Liquid-Phase Technologies Strengthen Manufacturing Scalability
    • Increased Outsourcing to CDMOs and CMOs Supports Cost-Efficient, Large-Volume API Production
    • Regulatory Support for Generic Peptides and Biosimilars Expands Addressable Market in Developing Regions
    • Integration of Automated Peptide Synthesizers Enhances Batch Reproducibility and Yield Optimization
    • Shift Toward Long-Acting Injectable Peptides Spurs Innovation in Sustained-Release API Formats
    • Surge in Personalized Medicine and Targeted Therapy Programs Throws the Spotlight on Custom Peptide APIs
    • Use of Novel Protecting Groups and Linkers Drives Improvement in Synthesis Efficiency and Product Stability
    • Growing Complexity of Multi-Peptide APIs Spurs Demand for Advanced Purification and Lyophilization Methods
    • Rising Investment in Peptide Drug Development Fuels Clinical Trial Activity and Commercial Pipeline
    • Expansion of GLP-1, GnRH, and Somatostatin Analog Classes Sustains Market Growth in Key Indications
    • Availability of GMP-Compliant Manufacturing Facilities Enhances Regulatory Approval Success Rates
    • Growing Focus on Peptide Oral Delivery Systems Encourages Innovation in Formulation Science
    • Strategic Collaborations Between Biotech Firms and API Manufacturers Accelerate Route-to-Market
    • Use of Peptide Conjugates and Fusion Molecules Expands Therapeutic Applications Across Disease Areas
    • Stringent Quality and Impurity Specifications Drive Investment in Analytical Testing Capabilities
    • Increase in Government Funding for Rare Disease Peptide Therapies Expands Innovation Incentives
    • Rising Demand for Cold Chain Storage and Transport of Peptide APIs Spurs Infrastructure Modernization
    • Emergence of Green Chemistry and Eco-Friendly Solvent Use Supports Sustainable Peptide Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Peptide API Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Peptide API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Peptide API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for GLP-1 Receptor Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for GLP-1 Receptor Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Peptide Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Peptide Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Peptide Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Type 2 Diabetes Mellitus Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Type 2 Diabetes Mellitus Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Type 1 Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Type 1 Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Type 1 Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Obesity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Obesity Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Non-alcoholic Fatty Liver Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Non-alcoholic Fatty Liver Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Non-alcoholic Fatty Liver Disease Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • JAPAN
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • CHINA
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • EUROPE
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Peptide API by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Peptide API by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • FRANCE
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • GERMANY
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Peptide API by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • INDIA
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Peptide API by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Peptide API by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Peptide API by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Peptide API by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Peptide API by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
  • AFRICA
    • Peptide API Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Peptide API by Drug Class - GLP-1 Receptor Agonist, Insulin and Other Peptide Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Peptide API by Drug Class - Percentage Breakdown of Value Sales for GLP-1 Receptor Agonist, Insulin and Other Peptide Classes for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Peptide API by Application - Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Peptide API by Application - Percentage Breakdown of Value Sales for Other Applications, Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application and Non-alcoholic Fatty Liver Disease Application for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Peptide API by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Peptide API by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Peptide API by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!